Whole–genome characterization of chemoresistant ovarian cancer AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ... Nature 521 (7553), 489-494, 2015 | 1552 | 2015 |
Rethinking ovarian cancer: recommendations for improving outcomes S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ... Nature Reviews Cancer 11 (10), 719-725, 2011 | 1533 | 2011 |
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ... Nature reviews Cancer 15 (11), 668-679, 2015 | 1211 | 2015 |
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019 | 1085 | 2019 |
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer GC Sellar, KP Watt, GJ Rabiasz, EA Stronach, L Li, EP Miller, CE Massie, ... Nature genetics 34 (3), 337-343, 2003 | 239 | 2003 |
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer EA Stronach, A Alfraidi, N Rama, C Datler, JB Studd, R Agarwal, ... Cancer research 71 (13), 4412-4422, 2011 | 203 | 2011 |
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer DS Matassa, MR Amoroso, H Lu, R Avolio, D Arzeni, C Procaccini, ... Cell Death & Differentiation 23 (9), 1542-1554, 2016 | 174 | 2016 |
DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance EA Stronach, M Chen, EN Maginn, R Agarwal, GB Mills, H Wasan, ... Neoplasia 13 (11), 1069-IN35, 2011 | 158 | 2011 |
Prognostic gene expression signature for high-grade serous ovarian cancer J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, ... Annals of Oncology 31 (9), 1240-1250, 2020 | 116 | 2020 |
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening G Picco, ED Chen, LG Alonso, FM Behan, E Gonçalves, G Bignell, ... Nature communications 10 (1), 2198, 2019 | 109 | 2019 |
Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following … EA Stronach, J Paul, KM Timms, E Hughes, K Brown, C Neff, M Perry, ... Molecular Cancer Research 16 (7), 1103-1111, 2018 | 108 | 2018 |
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival W Dai, JM Teodoridis, C Zeller, J Graham, J Hersey, JM Flanagan, ... Clinical Cancer Research 17 (12), 4052-4062, 2011 | 103 | 2011 |
Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells N Chapman-Rothe, E Curry, C Zeller, D Liber, E Stronach, H Gabra, ... Oncogene 32 (38), 4586-4592, 2013 | 97 | 2013 |
Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting F Iorio, FM Behan, E Gonçalves, SG Bhosle, E Chen, R Shepherd, ... BMC genomics 19, 1-16, 2018 | 95 | 2018 |
Comparing the characteristics of gene expression profiles derived by univariate and multivariate classification methods M Zucknick, S Richardson, EA Stronach Statistical applications in genetics and molecular biology 7 (1), 2008 | 91 | 2008 |
Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells S Ngan, EA Stronach, A Photiou, J Waxman, S Ali, L Buluwela Oncogene 28 (19), 2051-2063, 2009 | 86 | 2009 |
MicroRNAs associated with small bowel neuroendocrine tumours and their metastases HC Miller, AE Frampton, A Malczewska, S Ottaviani, EA Stronach, R Flora, ... Endocr Relat Cancer 23 (9), 711-726, 2016 | 68 | 2016 |
BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression GC Sellar, L Li, KP Watt, BD Nelkin, GJ Rabiasz, EA Stronach, EP Miller, ... Cancer research 61 (19), 6977-6981, 2001 | 68 | 2001 |
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer E de Wolf, MI Abdullah, SM Jones, K Menezes, DM Moss, FP Drijfhout, ... Scientific reports 7 (1), 5410, 2017 | 62 | 2017 |
The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma EA Stronach, P Cunnea, C Turner, T Guney, R Aiyappa, S Jeyapalan, ... Oncotarget 6 (31), 31593, 2015 | 57 | 2015 |